BCM
PLRX icon

Bronte Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Bronte Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,613
Closed -$23.5K – 66
2026
Q1 		$23.5K Hold
18,613
– – ﹤0.01% 50
2025
Q4 		$22.7K Buy
+18,613
New +$28K ﹤0.01% 40

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Bronte Capital Management's PLRX Position: Q2 2026 in Review

Bronte Capital Management sold out of Pliant Therapeutics (PLRX) in Q2 2026, closing a stake of 18,613 shares — an estimated $23.5K sold.

Bronte Capital Management first reported a position in PLRX in Q4 2025 and held it in 2 quarters. The position peaked at $23.5K in Q1 2026. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Bronte Capital Management reported no remaining Pliant Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bronte Capital Management sold 18,613 Pliant Therapeutics shares in Q2 2026, an estimated $23.5K.
  • Bronte Capital Management first reported a position in Pliant Therapeutics in Q4 2025 and held it in 2 quarters.
  • Bronte Capital Management's Pliant Therapeutics position peaked at $23.5K in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.